Home/Filings/4/0001209191-23-016401
4//SEC Filing

Nolan Mangini Siobhan 4

Accession 0001209191-23-016401

CIK 0001426332other

Filed

Mar 5, 7:00 PM ET

Accepted

Mar 6, 5:12 PM ET

Size

9.8 KB

Accession

0001209191-23-016401

Insider Transaction Report

Form 4
Period: 2023-03-02
Nolan Mangini Siobhan
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2023-03-02+76,00076,000 total
  • Award

    Stock Option (Right to Buy)

    2023-03-02+228,000228,000 total
    Exercise: $4.36Exp: 2033-03-01Common Stock (228,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2023-03-02+200,000200,000 total
    Exercise: $4.36Exp: 2033-03-01Common Stock (200,000 underlying)
Footnotes (3)
  • [F1]Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
  • [F2]The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.
  • [F3]1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date.

Issuer

NGM BIOPHARMACEUTICALS INC

CIK 0001426332

Entity typeother

Related Parties

1
  • filerCIK 0001679464

Filing Metadata

Form type
4
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 5:12 PM ET
Size
9.8 KB